Exact Mass: 358.1293

Exact Mass Matches: 358.1293

Found 183 metabolites which its exact mass value is equals to given mass value 358.1293, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Sweroside

(3S,4R,4aS)-4-ethenyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,4a,5,6-tetrahydro-3H-pyrano[3,4-c]pyran-8-one

C16H22O9 (358.1264)

Sweroside is a glycoside. Sweroside is a natural product found in Strychnos axillaris, Lonicera japonica, and other organisms with data available. See also: Lonicera japonica flower (part of); Menyanthes trifoliata leaf (part of); Centaurium erythraea whole (part of). Sweroside, isolated from Lonicera japonica, exhibits cytoprotective, anti-osteoporotic, and hepatoprotective effect[1][2]. Sweroside, isolated from Lonicera japonica, exhibits cytoprotective, anti-osteoporotic, and hepatoprotective effect[1][2].

Tarennoside

C16H22O9 (358.1264)

10-Deoxygeniposidic acid

C16H22O9 (358.1264)

202-791

isopropyl (4S)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-5-nitro-1,4-dihydropyridine-3-carboxylate

C17H18N4O5 (358.1277)

D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents > D002120 - Calcium Channel Agonists D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

CV 1808

2-Phenylaminoadenosine

C16H18N6O4 (358.1389)

D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents CV1808?(2-Phenylaminoadenosine) is a non-selective A2?adenosine receptor (A2 AR) agonist with Kis of 76 and 1450 nM for A2A and A3 adenosine receptor subtypes, respectively[1]. CV1808?(2-Phenylaminoadenosine) is a non-selective A2?adenosine receptor (A2 AR) agonist with Kis of 76 and 1450 nM for A2A and A3 adenosine receptor subtypes, respectively[1].

Phlorisobutyrophenone 2-glucoside

1-(2,4-dihydroxy-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-2-methylpropan-1-one

C16H22O9 (358.1264)

Phlorisobutyrophenone 2-glucoside is found in alcoholic beverages. Phlorisobutyrophenone 2-glucoside is a constituent of hops (Humulus lupulus)

2-Phenylaminoadenosine

2-[6-amino-2-(phenylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol

C16H18N6O4 (358.1389)

Selective A2 adenosine receptor agonist; potent coronary vasodilator; weak inhibitor of adenosine uptake by rat cerebral cortical synaptosomes; used as a vasodilator agent; is a potent anti-inflammatory agent, acting at its four G protein coupled receptors. Topical treatment of adenosine to foot wounds in diabetes mellitus has been shown in lab animals to drastically increase tissue repair and reconstruction. Topical administration of adenosine for use in wound healing deficiencies and diabetes mellitus in humans is currently under clinical investigation. Adenosine is a nucleoside comprised of adenine attached to a ribose (ribofuranose) moiety via a beta-N9-glycosidic bond. Selective A2 adenosine receptor agonist; potent coronary vasodilator; weak inhibitor of adenosine uptake by rat cerebral cortical synaptosomes; used as a vasodilator agent; is a potent anti-inflammatory agent, acting at its four G protein coupled receptors. Topical treatment of adenosine to foot wounds in diabetes mellitus has been shown in lab animals to drastically increase tissue repair and reconstruction. Topical administration of adenosine for use in wound healing deficiencies and diabetes mellitus in humans is currently under clinical investigation. D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents CV1808?(2-Phenylaminoadenosine) is a non-selective A2?adenosine receptor (A2 AR) agonist with Kis of 76 and 1450 nM for A2A and A3 adenosine receptor subtypes, respectively[1]. CV1808?(2-Phenylaminoadenosine) is a non-selective A2?adenosine receptor (A2 AR) agonist with Kis of 76 and 1450 nM for A2A and A3 adenosine receptor subtypes, respectively[1].

1,5-Benzothiazepin-4(5H)-one, 2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-5-(2-(methylamino)ethyl)-, (2S,3S)-

C19H22N2O3S (358.1351)

Sweroside

5-ethenyl-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1H,3H,4H,4aH,5H,6H-pyrano[3,4-c]pyran-1-one

C16H22O9 (358.1264)

2,4-dihydroxy-6-methoxy-3-methylacetophenone 4-O-beta-D-glucopyranoside|2,4-Dihydroxy-6-methoxy-3-methylacetophenone-4-O-??-D-glucopyranoside

C16H22O9 (358.1264)

methyl 3-(2-O-beta-D-glucopyranosyl-4-hydroxyphenyl)propanoate

C16H22O9 (358.1264)

2-O-(2)-??-D-Glucopyranosyl-4,6-dimethoxy phenylenthanone|4,6-dimethoxyacetophenone-2-O-beta-D-glucoside

C16H22O9 (358.1264)

7-deoxygardoside

C16H22O9 (358.1264)

iridolinaroside A

C16H22O9 (358.1264)

hydroquinone O-[6-(3-hydroxyisobutanoyloxy)]-beta-D-galactopyranoside

C16H22O9 (358.1264)

3-(4-beta-D-glucopyranosyloxy-3-methoxy-phenyl)-propionic acid|3-(4-beta-D-Glucopyranosyloxy-3-methoxy-phenyl)-propionsaeure

C16H22O9 (358.1264)

Coniferin

C16H22O9 (358.1264)

Latinone

C23H18O4 (358.1205)

C16H22O9

C16H22O9 (358.1264)

3-hydroxy-1-(4-O-beta-D-glucopyranosyl-3-methoxyphenyl)propan-1-one|specphenoside A

C16H22O9 (358.1264)

(-)-3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-1-propanone 3-O-beta-D-glucopyranoside|3-Me ether,3-O-beta-D-glucopyranoside-1-(3,4-Dihydroxyphenyl)-3-hydroxy-1-propanone|3,4-dihydroxy3methoxyropiophenone 3-O-beta-D-glucopyranoside|beta-hydroxypropiovanillone 3-O-beta-D-glucopyranoside

(-)-3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-1-propanone 3-O-beta-D-glucopyranoside|3-Me ether,3-O-beta-D-glucopyranoside-1-(3,4-Dihydroxyphenyl)-3-hydroxy-1-propanone|3,4-dihydroxy3methoxyropiophenone 3-O-beta-D-glucopyranoside|beta-hydroxypropiovanillone 3-O-beta-D-glucopyranoside

C16H22O9 (358.1264)

(Z)-4xi,9xi-Diacetoxy-6xi,7xi-epoxy-5xi-hydroxy-8-oxododeca-2-enoic acid

C16H22O9 (358.1264)

(R)-4-hydroxy-4-(3-hydroxyphenyl)butyric acid 4-O-beta-D-glucopyranoside|juglanoside H

C16H22O9 (358.1264)

SCHEMBL18585579

C16H22O9 (358.1264)

2,6-dimethoxyacetophenone-4-O-beta-D-glucoside

C16H22O9 (358.1264)

2-isobutyrylphloroglucinol-5-O-beta-D-glucopyranoside|5-[(2-methylpropanoyl)phloroglucinyl]-beta-D-glucopyranoside

C16H22O9 (358.1264)

11-Methoxy-1-methoxycarbonyl-8,13-dihydro-7H-indolo[2,3:3,4]pyrido[1,2-b]isochinolinium-betain|11-methoxy-1-methoxycarbonyl-8,13-dihydro-7H-indolo[2,3:3,4]pyrido[1,2-b]isoquinolinium betaine

C22H18N2O3 (358.1317)

Methyl syringate 4-O-alpha-L-rhamnopyranoside|Methyl Syringate alpha-L-Rhamnoside

C16H22O9 (358.1264)

2-n-Propyl-4-hydroxy-6-O-beta-L-glucopyranosylbenzoic acid

C16H22O9 (358.1264)

C16H22O9

NCGC00380819-01_C16H22O9_

C16H22O9 (358.1264)

C16H22O9_3-[2-(beta-D-Glucopyranosyloxy)-4-methoxyphenyl]propanoic acid

NCGC00180868-02_C16H22O9_3-[2-(beta-D-Glucopyranosyloxy)-4-methoxyphenyl]propanoic acid

C16H22O9 (358.1264)

C16H22O9_beta-D-Glucopyranoside, 2-(1,3-benzodioxol-5-yl)-3-hydroxypropyl

NCGC00385634-01_C16H22O9_beta-D-Glucopyranoside, 2-(1,3-benzodioxol-5-yl)-3-hydroxypropyl

C16H22O9 (358.1264)

C16H22O9_Methyl 4-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-3,5-dimethoxybenzoate

NCGC00384861-01_C16H22O9_Methyl 4-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-3,5-dimethoxybenzoate

C16H22O9 (358.1264)

3-[4-methoxy-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]propanoic acid

C16H22O9 (358.1264)

MMV688508

C19H19N2O4F (358.1329)

MMV030734

C17H19N6OCl (358.1309)

3-[4-methoxy-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]propanoic acid_major

C16H22O9 (358.1264)

Deacetyl-N-monodemethyldiltiazem

C19H22N2O3S (358.1351)

Deacetyl-O-demethyldiltiazem

C19H22N2O3S (358.1351)

2-Phenylaminoadenosine

C16H18N6O4 (358.1389)

Phlorisobutyrophenone 2-glucoside

1-(2,4-dihydroxy-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-2-methylpropan-1-one

C16H22O9 (358.1264)

Methyl 4-[(6-deoxy-?-L-mannopyranosyl)oxy]-3,5-dimethoxybenzoate

C16H22O9 (358.1264)

Tarrenoside

C16H22O9 (358.1264)

Potassium tetraphenylborate

C24H20BK (358.1295)

CMK

C18H19ClN4O2 (358.1196)

CMK is a RSK2 kinase inhibitor which exhibits similar potency but less chemical stability compared with FMK.

S-3-PHENYL-2-[N-(TRIFLUOROACETYL)PYRROLIDIN-2-YL]INDOLE

C20H17F3N2O (358.1293)

Dimethoxanate

C19H22N2O3S (358.1351)

R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent

4,4-(PIPERAZINE-1,4-DIYL)BIS(BUTANE-1-SULFONIC ACID)

C12H26N2O6S2 (358.1232)

Tributyl(2-furyl)stannane

C16H30OSn (358.1319)

boc-l-phe(4-nh-so2-ch3)

C15H22N2O6S (358.1199)

[1-ethyl-4-methyl-5-[(2-nitrophenyl)diazenyl]-6-oxopyridin-3-yl]methylurea

C16H18N6O4 (358.1389)

N-(2-CHLORO-PYRIDIN-3-YL)-4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-BENZAMIDE

C18H20BClN2O3 (358.1255)

2-Allyl-4,6-dibenzoylresorcinol

C23H18O4 (358.1205)

4-TERT-BUTOXYCARBONYLAMINO-1-(3,4-DICHLOROBENZYL)PIPERIDINE

C17H24Cl2N2O2 (358.1215)

ESCULETIN DIBENZYL ETHER

C23H18O4 (358.1205)

Ethyl 3-O-benzoyl-2-deoxy-2,2-difluoro-4,5-O-isopropylidene-D-ery thro-pentonate

C17H20F2O6 (358.1228)

1H-Indene-1-carboxylicacid

C15H22N2O6S (358.1199)

9(10H)-Anthracenone,10-(diphenylmethylene)-

C27H18O (358.1358)

4-(Chloromethyl)-1-trityl-1H-imidazole

C23H19ClN2 (358.1237)

(R)-BENZYL (4-(METHYLAMINO)-4-OXO-1-(PHENYLTHIO)BUTAN-2-YL)CARBAMATE

C19H22N2O3S (358.1351)

5-chloromethyl-1-methyl-1h-imidazole hcl

C23H19ClN2 (358.1237)

5,5-Bi-1,10-phenanthroline

C24H14N4 (358.1218)

O-Desacetyl-N-desmethyl Diltiazem

C19H22N2O3S (358.1351)

isopropyl (4S)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-5-nitro-1,4-dihydropyridine-3-carboxylate

C17H18N4O5 (358.1277)

2-{5-[Amino(iminio)methyl]-6-chloro-1H-benzimidazol-2-YL}-6-isobutoxybenzenolate

C18H19ClN4O2 (358.1196)

5-[2-(1-amino-2-methylpropan-2-yl)-5-(2-aminopyrimidin-4-yl)-1H-imidazol-4-yl]-2-chlorophenol

C17H19ClN6O (358.1309)

3,5-Dimethoxy-4-[(alpha-L-rhamnopyranosyl)oxy]benzoic acid methyl ester

C16H22O9 (358.1264)

Rabeprazole(1-)

C18H20N3O3S- (358.1225)

N-[(7-methyl-2-oxo-1H-quinolin-3-yl)methyl]-N-phenyl-2-furancarboxamide

C22H18N2O3 (358.1317)

N-(3,4-dimethylphenyl)-N-[(E)-(5-nitrofuran-2-yl)methylideneamino]butanediamide

C17H18N4O5 (358.1277)

O-Demethyldeacetyldiltiazem

Deacetyl-O-demethyldiltiazem

C19H22N2O3S (358.1351)

N-[3-[(cyclopropylamino)-oxomethyl]-4,5,6,7,8,9-hexahydrocycloocta[b]thiophen-2-yl]-2-furancarboxamide

C19H22N2O3S (358.1351)

N-[5-(1,3-benzoxazol-2-yl)-2-methylphenyl]-2-phenoxyacetamide

C22H18N2O3 (358.1317)

2-(1,3-dimethyl-2,4,6-trioxo-5,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)-N-(2-methoxyphenyl)acetamide

C17H18N4O5 (358.1277)

[4-(4-Hydroxyphenyl)-1-piperazinyl]-[2-methoxy-4-(methylthio)phenyl]methanone

C19H22N2O3S (358.1351)

ethyl 2-{[(E)-(2-hydroxy-5-methylphenyl)methylidene]amino}-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate

C19H22N2O3S (358.1351)

2-(2,4-dimethylphenoxy)-N-[(5-ethyl-2-hydroxyanilino)-sulfanylidenemethyl]acetamide

C19H22N2O3S (358.1351)

methyl (1R,9S,10S,11S)-5-(2-fluorophenyl)-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate

C19H19FN2O4 (358.1329)

methyl (1S,9R,10R,11R)-5-(2-fluorophenyl)-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxylate

C19H19FN2O4 (358.1329)

N-[[(5S)-3-[3-fluoro-4-[4-(hydroxymethyl)phenyl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide

C19H19FN2O4 (358.1329)

[3-[2,3-Dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] heptanoate

C13H27O9P (358.1393)

2-[6-amino-2-(phenylamino)-9H-purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol

C16H18N6O4 (358.1389)

D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

Phenylaminoadenosine

C16H18N6O4 (358.1389)

JHU37152

C19H20ClFN4 (358.136)

JHU37152 is a potent and brain-penetrant DREADD agonist, with EC50s of 5?nM and 0.5?nM for hM3Dq and hM4Di DREADDs in HEK-293 cells, respectively. JHU37152 exhibits selective [3H]Clozapine displacement from DREADDs and not from other Clozapine-binding sites in mice brain tissue[1].

JHU37160

C19H20ClFN4 (358.136)

JHU37160 is a potent and brain-penetrant DREADD agonist, with EC50s of 18.5?nM and 0.2?nM for hM3Dq and hM4Di DREADDs in HEK-293 cells, respectively. JHU37160 exhibits selective [3H]Clozapine displacement from DREADDs and not from other Clozapine-binding sites in mice brain tissue[1].

7-methylidene-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7ah-cyclopenta[c]pyran-4-carboxylic acid

C16H22O9 (358.1264)

(1r,4ar,7ar)-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid

C16H22O9 (358.1264)

6-methyl-8-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,9-dioxatricyclo[5.3.1.0⁴,¹¹]undec-1(10)-en-2-one

C16H22O9 (358.1264)

(5r,6s,7r,8r)-5,6,7,8,9-pentahydroxy-1-(4-hydroxy-3-methoxyphenyl)nonane-3,4-dione

C16H22O9 (358.1264)

(2s,3s,4e,6s,7s)-2-(acetyloxy)-6,7-dihydroxy-7-[(2r,3s)-3-hydroxy-6-oxo-2,3-dihydropyran-2-yl]hept-4-en-3-yl acetate

C16H22O9 (358.1264)

1-(2,6-dihydroxy-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-2-methylpropan-1-one

C16H22O9 (358.1264)

[(2r,3r,4s,5r,6s)-3,4,5-trihydroxy-6-(4-hydroxyphenoxy)oxan-2-yl]methyl (2s)-3-hydroxy-2-methylpropanoate

C16H22O9 (358.1264)

4-hydroxy-2-propyl-6-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzoic acid

C16H22O9 (358.1264)

2-(4-hydroxy-3-methoxyphenyl)-3,6-bis(hydroxymethyl)-hexahydro-2h-pyrano[2,3-b][1,4]dioxine-7,8-diol

C16H22O9 (358.1264)

(2s,3r,5ar,7r,8s,9s,9ar)-2-(4-hydroxy-3-methoxyphenyl)-7-(hydroxymethyl)-octahydropyrano[2,3-b][1,4]dioxepine-3,8,9-triol

C16H22O9 (358.1264)

1-(2,6-dimethoxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)ethanone

C16H22O9 (358.1264)

3-(4-methoxy-2-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)propanoic acid

C16H22O9 (358.1264)

methyl 3,5-dimethoxy-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]benzoate

C16H22O9 (358.1264)

2,3,4,5,6-pentahydroxyhexyl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C16H22O9 (358.1264)

2',4',6'-trihydroxy-3'-methylacetophenone; 6'-me ether,4'-o-beta-d-glucopyranoside

C16H22O9 (358.1264)

{"Ingredient_id": "HBIN004246","Ingredient_name": "2',4',6'-trihydroxy-3'-methylacetophenone; 6'-me ether,4'-o-beta-d-glucopyranoside","Alias": "NA","Ingredient_formula": "C16H22O9","Ingredient_Smile": "NA","Ingredient_weight": "358.34","OB_score": "NA","CAS_id": "145194-40-7","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8908","PubChem_id": "NA","DrugBank_id": "NA"}

2,4-dihydroxy-6-methoxy-3-methyl-acetophenone-4-o-beta-d-glucopyranoside

2,4-dihydroxy-6-methoxy-3-methylaceto-phenone-4-o-β-d-glucopyranoside

C16H22O9 (358.1264)

{"Ingredient_id": "HBIN004325","Ingredient_name": "2,4-dihydroxy-6-methoxy-3-methyl-acetophenone-4-o-beta-d-glucopyranoside","Alias": "2,4-dihydroxy-6-methoxy-3-methylaceto-phenone-4-o-\u03b2-d-glucopyranoside","Ingredient_formula": "C16H22O9","Ingredient_Smile": "CC(=O)C1=CC(=C(C(=C1)OC)OC2C(C(C(C(O2)CO)O)O)O)OC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25893;5988","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

2-o-(2)-β-d-glucopyranosyl-4,6-dimethoxyphenylenthanone

C16H22O9 (358.1264)

{"Ingredient_id": "HBIN006160","Ingredient_name": "2-o-(2)-\u03b2-d-glucopyranosyl-4,6-dimethoxyphenylenthanone","Alias": "NA","Ingredient_formula": "C16H22O9","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "8624","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

2-o-β-d-glucosyloxy-4-methoxybenzene-propanoicacid

C16H22O9 (358.1264)

{"Ingredient_id": "HBIN006205","Ingredient_name": "2-o-\u03b2-d-glucosyloxy-4-methoxybenzene-propanoicacid","Alias": "NA","Ingredient_formula": "C16H22O9","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "8756","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}